Embla Medical (EMBLA) investor relations material

Company overview and market position

• Global leader in innovative mobility solutions, operating ~200 patient care facilities in 12 markets and direct sales in ~40 markets with 4,500 employees.

• Founded in 1971, listed on Nasdaq Copenhagen since 2009, with a market cap of ~$2bn.

• Recognized for sustainable growth, named one of the World's Best Companies in Sustainable Growth 2026 by TIME Magazine.

• Business model is highly recurring, with 90% reimbursed sales and 70-80% recurring revenue at the end-user level.

• Holds a 25% market share in a $2bn prosthetics market growing 6-8% annually.

Financial performance and growth strategy

• Achieved record sales of $929m in 2025, with 6% organic growth and 7% LCY growth including M&A.

• EBITDA margin reached 20% in 2025, on par with 2024, with ambitions to gradually increase.

• Growth'27 strategy targets 7-10% average annual sales growth, including 5-7% organic and 2-3% from M&A.

• 2026 guidance narrowed to 5-7% organic sales growth and 20-22% EBITDA margin.

• Strong track record of delivery, with consistent sales and EBITDA growth from 2022 to 2025.

Innovation and technology leadership

• Invests ~$50m annually in R&D, equivalent to 7-8% of product sales, focusing on premium solutions.

• Holds over 2,000 patents, positioning as a technology leader in bionic and neuro orthotic solutions.

• Drives growth through innovation, functional trade-up, and expanding bionic penetration.

• Progressing toward advanced neural integration and biohybrid prosthetics for seamless user experience.

• Bionic MPK market expanding due to innovation, reimbursement, and regional coverage.